A study from Israel indicates that people who received the Pfizer/BioNTech coronavirus vaccine develop an immune response significantly stronger than COVID-19 survivors. These researchers think this sort of immunity might completely prevent COVID-19 >>
Pfizer and BioNTech announced they completed testing that shows the key mutation present on the UK and South African coronavirus strains would not create resistance to the vaccine. Researchers tested sera containing antibodies >>
Pfizer CEO Dr. Albert Bourla said in an interview there are “no safety concerns” for the BioNTech coronavirus vaccine that has shown effecacy of 90%, according to interim Phase 3 results. The CEO >>
The first interim results for one of the leading coronavirus vaccine candidates have arrived, showing incredibly promising efficacy results. According to the first batch of data, the Pfizer/BioNTech mRNA vaccine is 90% effective >>
The company making the only coronavirus vaccine with a theoretical chance of being approved before the US presidential election made it clear such a timeline is unfeasible. Pfizer CEO Albert Bourla said his >>
The only coronavirus vaccine candidate that still has a chance of being approved for emergency use by election day is being fast-tracked in Europe as well. Moderna and AstraZeneca face a few delays >>
A second coronavirus vaccine trial has entered the final stage of testing, and the research could be finalized as soon as October. One of the BioNTech/Pfizer vaccine candidates that were studied in preclinical >>
The latest coronavirus vaccine development update comes from the US government, which inked a new deal for a promising vaccine made by BioNTech and Pfizer. The government pledged nearly $2 billion to secure >>
